Slide 1: TechKnow
For personal use only TechKnow Gary Phillips – CEO 19 & 21 August 2025
Slide 2: Forward looking statement
Forward looking statement For personal use only This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cau
Slide 3: Investment Highlights
Investment Highlights For personal use only Australian-founded clinical Clinical Backed by specialist Focus on first-in-class and Funded into 2027 with near stage drug developer. stage drug developer. healthcare investors – best-in-class drugs backed term data to drive value 49% institutional. by in
Slide 4: Shareholders & Cash
Shareholders & Cash Financial Information (ASX: SNT) Share Price & Volume - YTD For personal use only Share Price Share price – 15 August 2025 $0.027 0.1 0.09 Market cap A$43.9m 0.08 0.07 Cash balance (30 Jun 2025) A$15.1m 0.06 0.05 0.04 Enterprise value A$28.8m 0.03 0.02 0.01 Institutional Ownershi
Slide 5: Pipeline Poised To Deliver Near Term Value
Pipeline Poised To Deliver Near Term Value For personal use only Phase 1 Target Drug Indication Preclinical Phase 2 Status Partner(s) Healthy Patients participants Myelofibrosis Active; fully recruited Amsulostat AZALOX trial Pan-LOX (SNT-5505) recruiting Myelodysplastic Syndrome Protocol under revi
Slide 6: Global Leader in Lysyl Oxidases
Global Leader in Lysyl Oxidases Multi year research program leveraged with international scientific collaborations has delivered three drugs in Phase 1c/2 trials For personal use only Lysyl oxidases mediate the final stage in Amsulostat (SNT-5505) in Topical pan-LOX inhibitors fibrosis Oncology in S
Slide 7: Myelofibrosis
Myelofibrosis A rare type of bone marrow cancer that disrupts the body’s normal production of blood cells For personal use only Myelofibrosis characterised by a build up of scar tissue (fibrosis) in Key Facts bone marrow and abnormal proliferation of blood precursor cells reducing the production of
Slide 8: Myelofibrosis: Limited treatment options currently
Myelofibrosis Limited treatment options currently For personal use only Current standard of care (SoC): JAK inhibitors Amsulostat (SNT-5505) Key• Class Factsof drugs used in the management of splenomegaly In contrast to SoC, amsulostat intervenes at the source, (enlarged spleen) and other constituti
Slide 9: Total Symptom Score
Total Symptom Score 73% (8/11) of patients achieved TSS50 at Week 24 or beyond Reduction at W24 Additional reduction past W24 For personal use only ▪ At Week 24 # Pt completed W52 and study * Pt reached W38 and is ongoing ▪ Median absolute change -6 Baseline TSS (range -2 to -20) 37 10 52# 32 11* 18
Slide 10: Spleen Volume Reduction
Spleen Volume Reduction 44% (4/9) of patients achieved SVR25 at Week 24 or beyond Reduction at W24 For personal use only Additional reduction past W24 ▪ At Week 24 # Pt completed W52 and study * Pt reached W38 and is ongoing ▪ 2/11 pts not evaluable for SVR 20 Baseline Spleen Volume (cm3) (SV < 450
Slide 11: Conclusions
Conclusions Interim data1 suggests that amsulostat combined with ruxolitinib may deliver deep and long-lasting benefit to patients who are sub-optimally controlled on ruxolitinib alone For personal use only Consistent with Despite the relatively Reductions in Remaining 3 patients monotherapy data2,
Slide 12: FDA Clinical Development Guidance for amsulostat in myelofibrosis (MF)
FDA Clinical Development Guidance for amsulostat in myelofibrosis (MF) Syntara Proposal FDA Guidance For personal use only • Progress directly to pivotal • Conduct Phase 2b study with placebo-controlled Phase 3 study control arm • ~300 patients • ~100 patients • 3-year duration • 2-year duration • ~
Slide 13: Implications of FDA Guidance
Implications of FDA Guidance • Doesn’t diminish potential value of amsulostat in MF For personal use only • Clear pathway forward • Opportunity to engage with FDA in Q1 2026 on Phase 2b trial design • Reduced cash requirement for Phase 2b vs Phase 3 clinical study • Phase 2b significantly de-risks P
Slide 14: Strong interest in MF assets from strategics
Strong interest in MF assets from strategics Target / Acquiror / / / / For personal use only Date of Announcement Dec-2024 Feb-2024 June-2023 July-2022 Drug Name Elritercept Pelabresib Pacritinib Momelotinib Lead Indication / MDS and MF Myelofibrosis Myelofibrosis Myelofibrosis Phase (at transaction
Slide 15: Skin Scarring
Skin Scarring Cutaneous scarring following skin trauma or a wound is a major cause of morbidity and disfigurement For personal use only Hypertrophic scars and keloids are Current standard Potential for pan-LOX Key Facts cosmetically and functionally of care (SoC): inhibition • 100m patients develop
Slide 16: Syntara, UWA and Fiona Wood Foundation
Syntara, UWA and Fiona Wood Foundation Long-term collaboration driving translation of basic science into the clinic and patient benefit For personal use only ▪ Multi-year pre-clinical program SOLARIA2 Findings ▪ Completed clinical studies • Solaria 1; SNT-6302 healthy volunteers • Solaria 2; SNT-630
Slide 17: SNT-9465: Next generation topical inhibitor
SNT-9465: Next generation topical inhibitor SNT-6302 / SOLARIA2 provided proof of concept SNT-9465 Phase 1a/b study design For personal use only • Incidences of skin redness suggested potential • Phase 1a Single Ascending Dose development limitations for SNT-6302 • Healthy volunteer, (N=24) • 3 dose
Slide 18: Recent & Anticipated News Flow
Recent & Anticipated News Flow Strong and growing pipeline with advancement in studies expected to provide value inflection points For personal use only June 2025 Mid 2025 Mid 2025 Q3 2025 Q3-Q4 2025 • FDA grants Fast Track Amsulostat Phase SNT-9465 Phase 1a/b • FDA feedback on Amsulostat Phase 1c/2
Slide 19: Gary Phillips, Chief Executive Officer
For personal use only Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au www.syntaraTX.com.au LinkedIn Twitter Logo WhiteOnBlue